Neogen Corp.
- NEOG · Nasdaq
- In Vitro & In Vivo Diagnostic Substances
- Lansing, MI
- 2,636 employees
- CIK 0000711377
Updated from SEC filings through
Top things to know
Executives
-
Mike Nassif President & Chief Executive Officer DEF 14A, 2026-08-21 - Mikheal Nassif CEO 4, 2026-08-20
- John Edward Adent Former CEO 4, 2025-10-28
- Richard Bryan Riggsbee CFO 4, 2026-08-14
-
R. Bryan Riggsbee Chief Financial Officer 10-K, 2026-07-30 - David H. Naemura Former CFO 4, 2025-12-02
What leadership is saying
“As we entered fiscal year 2027, our focus shifted from strengthening fundamentals to scaling them to drive more consistent execution, improved customer outcomes and profitable growth”
Earnings press release (8-K Ex. 99.1), filed October 6, 2026
Neogen Corp is a U.S. public company in in vitro & in vivo diagnostic substances (SIC 2835), headquartered in Lansing, MI. It trades as NEOG on Nasdaq. Revenue was $870M in the fiscal year ending May 31, 2026, -2.7% from the year before. It reported about 2,636 employees. Mike Nassif is President & Chief Executive Officer.
Five-year financials
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $870M 10-K, 2026-07-30 | $895M 10-K, 2026-07-30 | $924M 10-K, 2026-07-30 | $822M 10-K, 2025-07-30 | $527M 10-K, 2024-07-30 |
| Operating income | -$21.6M 10-K, 2026-07-30 | -$1.1B 10-K, 2026-07-30 | $58.6M 10-K, 2026-07-30 | $37.5M 10-K, 2025-07-30 | $58.6M 10-K, 2024-07-30 |
| SG&A | $412M 10-K, 2026-07-30 | $402M 10-K, 2026-07-30 | $383M 10-K, 2026-07-30 | $342M 10-K, 2025-07-30 | $167M 10-K, 2024-07-30 |
| Net income | -$7.9M 10-K, 2026-07-30 | -$1.1B 10-K, 2026-07-30 | -$9.4M 10-K, 2026-07-30 | -$22.9M 10-K, 2025-07-30 | $48.3M 10-K, 2024-07-30 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Mike Nassif CEO | Global Life Sciences Executive | Board Director | Proven Operator in MedTech & Diagnostics | President & Chief Executive Officer | DEF 14A, 2026-08-21 |
| Mikheal Nassif | CEO | 4, 2026-08-20 |
| John Edward Adent | Former CEO | 4, 2025-10-28 |
| John E. Adent | Named in proxy bio: (Former) President & Chief Executive Officer | DEF 14A, 2025-09-12 |
| Richard Bryan Riggsbee | CFO | 4, 2026-08-14 |
| R. Bryan Riggsbee | Chief Financial Officer | 10-K, 2026-07-30 |
| David H. Naemura | Former CFO | 4, 2025-12-02 |
| Jeremy Yarwood | Chief Scientific Officer | 4, 2026-11-04 |
| Joe B. Freels | Chief Commercial Officer | 4, 2026-11-03 |
| Kevin M. Burke | Chief HR Officer | 3, 2026-10-30 |
| John Patrick Moylan | Chief Accounting Officer | 4, 2026-08-20 |
| Tamara A. Ranalli SVP & GM, Global Food Safety | Senior Vice President | 4, 2026-08-14 |
| Jennifer Evans Stacey | Chief Legal Officer | 4, 2026-08-14 |
| John P. Moylan | Chief Accounting Officer | 10-K, 2026-07-30 |
| Amy M. Rocklin Chief Legal & Compliance Officer | Corporate Secretary | Former Chief Legal Officer | 4, 2026-05-19 |
| Douglas E. Jones | Named in proxy bio: Chief Operating Officer (Retired) | DEF 14A, 2025-09-12 |
What Neogen Corp does
Neogen Corporation and its subsidiaries develop, manufacture and market a diverse line of products and services dedicated to food and animal safety., culture media) sold to food and animal feed producers and processors to preserve the safety and quality of food to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. These products also ensure the general hygiene of the food manufacturing environment. We also have products to determine food quality and nutritional components.
Shares and governance
| Shares outstanding | 218.3 million (as of August 31, 2026) | 10-Q, October 7, 2026 |
|---|---|---|
| Public float | $972M (as of November 30, 2025) | 10-K, July 30, 2026 |
| Reportable segments | 2 (period ending August 31, 2026) | 10-Q, October 7, 2026 |
| Latest proxy statement | Meeting August 21, 2026 (filed August 21, 2026) | DEF 14A, August 21, 2026 |
| Auditor | Bdo Usa, P.c. (Grand Rapids, MI) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 4, 2026 | Jeremy Yarwood Chief Scientific Officer | Sale | 9,051 | $115K | Form 4, November 4, 2026 |
| October 9, 2026 | Mikheal Nassif CEO | Buy | 505 | $6K | Form 4, October 9, 2026 |
| August 4, 2026 | Mikheal Nassif CEO | Buy | 370 | $4K | Form 4, August 6, 2026 |
| February 17, 2026 | Mikheal Nassif CEO | Buy | 23 | $251.62 | Form 4, February 17, 2026 |
| February 2, 2026 | Mikheal Nassif CEO | Buy | 49 | $486.5 | Form 4, February 2, 2026 |
| January 16, 2026 | Mikheal Nassif CEO | Buy | 137 | $1K | Form 4, January 16, 2026 |
| November 3, 2025 | Mikheal Nassif CEO | Buy | 177 | $1K | Form 4, November 7, 2025 |
Recent 8-K events
- 8-K filed 2026-11-04
- Item 8.01 Other events
- 8-K filed 2026-10-07
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-10-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-07
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-07-30
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-20
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-04-09
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-30
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-01-08
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-10-30
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 8.01 Other events
Frequently asked questions about Neogen Corp
- What does Neogen Corp do?
- In its own words, from Item 1 of its 10-K: "Neogen Corporation and its subsidiaries develop, manufacture and market a diverse line of products and services dedicated to food and animal safety., culture media) sold to food and animal feed producers and processors to preserve the safety and quality of food to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. These products also ensure the general hygiene of the food manufacturing environment. We also have products to determine food quality and nutritional components."
- What is Neogen Corp's revenue?
- $870M for the fiscal year ending May 31, 2026, from its 10-K filed July 30, 2026.
- Is Neogen Corp profitable?
- Neogen Corp reported net income of -$7.9M for the fiscal year ending May 31, 2026.
- How many employees does Neogen Corp have?
- About 2,636 as of May 31, 2026, as stated in its annual report.
- Who is the CEO of Neogen Corp?
- Mike Nassif, President & Chief Executive Officer, as named in a DEF 14A filed August 21, 2026.
- Who is the CFO of Neogen Corp?
- Richard Bryan Riggsbee, CFO, as named in a 4 filed August 14, 2026.
- Where is Neogen Corp headquartered?
- Lansing, MI.
- What is Neogen Corp's stock ticker?
- NEOG on Nasdaq.
- What industry is Neogen Corp in?
- In Vitro & In Vivo Diagnostic Substances, SIC code 2835.
- What is Neogen Corp's website?
- neogen.com.
- When does Neogen Corp report earnings next?
- January 5, 2027. Source: estimate_8k_pattern.
- Is Neogen Corp a public company?
- Yes. Neogen Corp files with the SEC under CIK 0000711377 and trades as NEOG.
- Who audits Neogen Corp?
- Bdo Usa, P.c., Grand Rapids, MI, as named in its latest annual report (10-K).
- How many shares of Neogen Corp are outstanding?
- 218.3 million shares as of August 31, 2026, from its 10-Q filed October 7, 2026.
- What is Neogen Corp's public float?
- $972M as of November 30, 2025, as reported on the cover of its 10-K filed July 30, 2026.
- How many business segments does Neogen Corp report?
- 2 reportable segments for the period ending August 31, 2026, from its 10-Q filed October 7, 2026.
- When is Neogen Corp's annual shareholder meeting?
- August 21, 2026, per its proxy statement (DEF 14A) filed August 21, 2026.
- Have Neogen Corp insiders traded stock recently?
- Since November 3, 2025, officers and directors reported 1 open-market sale worth about $115K and 6 purchases worth about $14K on Forms 4 and 5. The most recent: Jeremy Yarwood (Chief Scientific Officer) sold 9,051 shares on November 4, 2026.